{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-027549","form_type":"8-K","ticker":"ETON","cik":"0001710340","company_name":"Eton Pharmaceuticals, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.943997+00:00","generated_at":"2026-06-11T18:22:25.469917+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Eton Pharma Q2 net income $4.6M, product sales +175% YoY; full-year revenue guidance raised to ~$30M","bullets":["Net income of $4.6M ($0.18 per share) vs net loss of $1.6M a year ago.","Product sales and royalty revenue of $6.5M, up 175% YoY and 22% sequentially; 10th straight quarter of growth.","Total Q2 revenue of $12.0M, including $5.5M from sale of neurology royalty interests.","Raised full-year revenue guidance to approximately $30M; launched Betaine Anhydrous in May.","ET-400 NDA submission on track for Q4 2023; cash $21.6M at quarter-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-027549","json":"https://secwatch.observer/filing/0001493152-23-027549.json","markdown":"https://secwatch.observer/filing/0001493152-23-027549.md","text":"https://secwatch.observer/filing/0001493152-23-027549.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710340/000149315223027549/0001493152-23-027549-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710340/000149315223027549/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T18:22:25.469917+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"342e22c0f6d1d2c2b7c310866ebc4e6bc8b45cd5","claim":"Eton Pharmaceuticals, Inc. reported full year 2023 results: revenue approximately $30 million in total revenue this year. Guidance raised.","evidence_excerpt":"Given our strong performance through the first half of the year, we have increased our revenue expectation and now anticipate reaching approximately $30 million in total revenue this year,\" said Sean Brynjelsen, CEO of Eton Pharmaceuticals.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1710340/000149315223027549/0001493152-23-027549-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"approximately $30 million in total revenue this year"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"507330f81ae190ab4e92401d6e5bd85118faa405","claim":"Eton Pharmaceuticals, Inc. reported second quarter ended June 30, 2023 results: revenue $12.0 million, net income $4.6 million, EPS $0.18 per basic and diluted share.","evidence_excerpt":"Net Revenue: Net sales for the second quarter of 2023 were $12.0 million compared with $7.4 million in the prior year period. Net sales included $5.5 million of licensing payments received during the quarter related to the sale of Eton’s neurology product royalties and milestones to Azurity Pharmaceuticals, compared to $5.0 million of licensing revenue in the prior year period related to the sale of multiple hospital products to Dr. Reddy’s. Product sales and royalty revenue were $6.5 million for the second quarter of 2023 compared with $2.4 million in the prior year period, an increase of 175% over the prior year period and 22% over the first quarter of 2023. The year-over-year increase in product sales and royalty revenue was primarily driven by growth in ALKINDI SPRINKLE and Carglumic Acid tablets. Gross Profit : Gross profit for the second quarter of 2023 was $9.7 million compared with $4.6 million in the prior year period. The growth was driven by the sale of the Company’s neurolo","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1710340/000149315223027549/0001493152-23-027549-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"$12.0 million"},{"label":"Net income","value":"$4.6 million"},{"label":"EPS","value":"$0.18 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}